New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
09:11 EDTBKS, CVRR, PXD, SQBG, OMI, MDCI, GLNG, AERI, NSPH, BMY, GIS, MON, IMSOn The Fly: Pre-market Movers
HIGHER: Barnes & Noble (BKS), up 7.7% after board authorizes management to separate Retail, Nook Media units... Monsanto (MON), up 5% after reporting better than expected Q3 results, raising its full year EPS outlook to the upper end of its previous guidance range and announcing a new $10B share repurchase authorization... IMS Health (IMS), up 7.7% after acquiring certain Cegedim businesses for $520M... Nanosphere (NSPH), up 16.2% after receiving 510(k) clearance for bacterial portion of Verigene EP test... Aerie Pharmaceuticals (AERI), up 37% after its trial of Roclatan achieved its primary efficacy endpoint... Medical Action (MDCI), up 94% after Owens & Minor (OMI) acquires the company for $13.80 per share in cash... Sequential Brands (SQBG), up 15% after acquiring Galaxy Brand for $100M cash, 13.75M shares... Pioneer Natural (PXD), up 2.3% after media reports that the company got U.S. permission to ship a type of light oil known as condensate... Bristol-Myers Squibb (BMY), up 2% after a Phase 3 study of nivolumab was halted early due to superior data. LOWER: General Mills (GIS), down 3.7% after Q4 earnings fall below analyst's consensus... Lindsay Corp. (LNN), down 5% after earnings miss, saying Iraq contract now more difficult to complete... Golar LNG (GLNG), down 2% after 11M share offering priced at $54 per share... CVR Refining (CVRR), down 7% after 6M share secondary offering of common units price at $26.07.
News For BKS;MON;GIS;BMY;NSPH;AERI;GLNG;MDCI;OMI;SQBG;PXD;CVRR;IMS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 16, 2014
07:23 EDTAERIIBF Conferences to hold a summit
Ophthalmology Innovation Summit is being held in Chicago on October 16.
06:16 EDTBMYBristol-Myers upgraded to Outperform from Market Perform at BMO Capital
October 15, 2014
10:43 EDTGLNGGolar LNG volatility elevated on sharp price movement
Golar LNG November call option implied volatility is at 98, December is at 86, January is at 80; compared to its 26-week average of 48 according to Track Data, suggesting large near term price movement.
09:57 EDTBMYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
October 14, 2014
11:23 EDTBMYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
17:24 EDTGISS&P announces changes to the S&P MidCap 400 and S&P SmallCap 600 indices
Subscribe for More Information
09:21 EDTNSPHOn The Fly: Pre-market Movers
Subscribe for More Information
08:09 EDTNSPHNanosphere reports FDA clearance for Verigene EP Nucleic Acid Test
Nanosphere announced it has received 510(k) clearance from the FDA for its Verigene Enteric Pathogens Nucleic Acid Test, or EP, which now includes additional viral targets, as well as the bacterial and toxigenic targets cleared by FDA earlier this summer.
08:05 EDTBMYBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:45 EDTMONU.S. chemical company declines an overreaction to macro outlook, says UBS
Subscribe for More Information
07:15 EDTGISNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTBMYBioFlorida to hold a conference
Subscribe for More Information
October 12, 2014
17:20 EDTMONGE, Splunk, Cisco, others could benefit from Internet of Things, Barron's says
Subscribe for More Information
October 10, 2014
12:32 EDTPXDPioneer Natural volatility elevated on wide share price movement
Pioneer Natural October call option implied volatility is at 41, November is at 44, January is at 35; compared to its 26-week average of 32 according to Track Data, suggesting large near term price movement.
12:11 EDTGLNGOptions with increasing implied volatility
Subscribe for More Information
12:05 EDTMONUSDA raises U.S. corn production estimate to 14.475B
Subscribe for More Information
10:03 EDTBMYBristol-Myers receives orphan status for melanoma treatment
Subscribe for More Information
10:01 EDTPXDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 2U (TWOU) initiated with an Outperform at Pacific Crest... Bloomin' Brands (BLMN) initiated with an Outperform at BMO Capital... Brinker (EAT) initiated with a Market Perform at BMO Capital... Buffalo Wild Wings (BWLD) initiated with an Outperform at BMO Capital... Chipotle (CMG) initiated with a Market Perform at BMO Capital... Chuy's (CHUY) initiated with a Market Perform at BMO Capital... Darden (DRI) initiated with a Market Perform at BMO Capital... EMC (EMC) initiated with a Buy at Jefferies... EPR Properties (EPR) initiated with a Buy at BofA/Merrill... HP (HPQ) initiated with a Hold at Jefferies... IBM (IBM) initiated with an Underperform at Jefferies... McDermott (MDR) initiated with an In-Line at Imperial Capital... NetApp (NTAP) initiated with a Hold at Jefferies... New Residential (NRZ) initiated with a Neutral at Piper Jaffray... Nimble Storage (NMBL) initiated with a Buy at Jefferies... Noodles & Company (NDLS) initiated with an Outperform at BMO Capital... PDC Energy (PDCE) initiated with an Overweight at Stephens... Panera Bread (PNRA) initiated with a Market Perform at BMO Capital... Pioneer Natural (PXD) initiated with an Outperform at Imperial Capital... Resource America (REXI) initiated with a Buy at MLV & Co.... Rex Energy (REXX) initiated with an Overweight at Stephens... Seagate (STX) initiated with a Buy at Jefferies... Silicon Motion (SIMO) initiated with a Buy at Brean Capital... Texas Roadhouse (TXRH) initiated with a Market Perform at BMO Capital... W.P. Carey (WPC) initiated with a Neutral at BofA/Merrill... Wayfair (W) initiated with a Buy at Janney Capital...Western Digital (WDC) initiated with a Buy at Jefferies... Yelp (YELP) initiated with a Buy at Sterne Agee.
08:19 EDTBMYMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
06:43 EDTGLNGGolar LNG recent weakness overdone, says BofA/Merrill
BofA/Merrill said recent weakness in Golar LNG is overdone and that sold LNG transport fundamentals remain in place. Shares are Buy rated.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use